BEVERLY, Mass., May 09, 2012 (BUSINESS WIRE) -- American Renal Associates Holdings, Inc. and its subsidiary American Renal Holdings Inc. announced today they will host a first quarter 2012 earnings call on Thursday, May 10, 2012 at 5:00 p.m. EDT. The live call can be accessed by dialing either 1-877-407-8029 or 201-689-8029.

Prior to the earnings conference call, American Renal Associates Holdings, Inc. will issue a press release summarizing its and American Renal Holdings Inc. first quarter 2012 earnings.

About American Renal Associates American Renal Associates Holdings, Inc. is the parent of American Renal Holdings Inc. and American Renal Associates LLC ("ARA") and is a leading owner and provider of outpatient kidney dialysis facilities operating facilities in partnership with nephrologists throughout the United States. The Company's unique operating philosophy merges physician autonomy, leading edge patient care and financial partnership between the nephrologists and ARA. Consequently, ARA has become one of the largest providers of outpatient kidney dialysis services in the nation with 112 owned facilities as of March 31, 2012 which are located in 19 states and the District of Columbia. For more information, visit www.americanrenal.com .

SOURCE: American Renal Associates Holdings, Inc.

        
        American Renal Associates Holdings, Inc. 
        Jonathan Wilcox, 978-922-3080 ext. 385 
        Chief Financial Officer
        

Copyright Business Wire 2012

...

Kamyar Kalantar-Zadeh, M.D., M.P.H., Ph.D., principal investigator at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed), is the author of an invited editorial in JAMA. The editorial accompanied a study that included data from more than 1 million adults, and indicated the use of a newer risk prediction equation that classified fewer individuals as having chronic kidney disease and more accurately categorized the risk for death and end-stage renal disease. The study and its accompanying editorial were published in the May 9 issue of JAMA.

Glomerular filtration rate (GFR) is used in the diagnosis of chronic kidney disease (CKD) and is an independent predictor of all-cause and cardiovascular mortality and kidney failure in a wide range of populations, according to background information in the article. Clinical guidelines recommend reporting estimated GFR when serum creatinine level is measured. "The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation more accurately estimates GFR than the Modification of Diet in Renal Disease (MDRD) Study equation using the same variables [age, sex, race, and serum creatinine level], especially at higher GFR, but definitive evidence of its risk implications in diverse settings is lacking," the authors write.

Kunihiro Matsushita, M.D., Ph.D., of Johns Hopkins University, Baltimore, and colleagues conducted a study to evaluate whether estimated GFR calculated by the CKD-EPI equation predicts risk for adverse outcomes more accurately than the MDRD Study equation in a broad range of populations. The study consisted of a meta-analysis of data from 1.1 million adults (18 years of age and older) from 25 general population cohorts, 7 high-risk cohorts (of vascular disease), and 13 CKD cohorts. The participants were from 40 countries or regions of Asia,

Europe, North America and South America, the Middle East, and Oceania. Data transfer and analyses were conducted between March 2011 and March 2012. The primary adverse outcomes analyzed were all-cause mortality (84,482 deaths from 40 cohorts), cardiovascular mortality (22,176 events from 28 cohorts), and end-stage renal disease (ESRD) (7,644 events from 21 cohorts).

The prevalence of CKD stages 3 to 5 (<60 mL/min/1.73 m2) was lower by the CKD-EPI equation than by the MDRD Study equation in the general population cohorts (6.3 percent vs. 8.7 percent, respectively) and in the high-risk cohorts (14.6 percent vs. 17.7 percent).

...

Patients of 53 renal units across the UK are accessing results and clinical letters through a secure online system, often meaning they get the information faster than their GPs.

Renal PatientView is used by 19,000 patients who have opted in to accessing their results online. The system also lets patients add their own data - such blood pressure - access online information about their condition and is being adapted to allow them to pass comments on their care back to hospital units.

Dr Keith Simpson, consultant nephrologist at the Western Infirmary in Glasgow, told the HC2012 conference in London that data is extracted from renal units' systems every six to 24 hours, depending on its importance. It is sent in encrypted form across NHS networks to a secure online server for patients to access. "The patient will normally see this before their GP," he said, as renal units do not generally send results and letters to GPs electronically.

The system, which was launched in 2005 and developed by staff from Glasgow's Western Infirmary and Edinburgh's Royal Infirmary, runs on open source software available for others to use. Units pay a fee to join, while it is free for patients. A similar system for bowel disease patients, using the software, will start this year.

Simpson said that many users log on to the system on the first day following a test, and a substantial number do likewise, just before an appointment. "Doctor may want to take note of this," he said. "Patients are very well-informed, and want to take part." Users tend to log on during work days, rather than weekends and bank holidays.

The system requires just a username and password for access, but Simpson said that research with users found that very few were concerned about security, that 40% shared their passwords with other people and that many thought the data should also be used for research.

He said that future plans for the system include allowing records to be transferred between different participating renal units, linking to primary care systems such as Scotland's emergency care summary and England's summary care record, and functionality for rare diseases. So far, no work has been done on whether it improves clinical outcomes for patients.

This article was originally published at Guardian Government Computing.

Guardian Government Computing is a business division of Guardian Professional, and covers the latest news and analysis of public sector technology. For updates on public sector IT, join the Government Computing Network here.

...

Hyderabad, Andhra Pradesh -- (SBWIRE) -- 05/08/2012 -- “Canada Nephrology and Urology Devices Market Outlook to 2018 - Incontinence Devices, Renal Dialysis Equipment and Lithotripters” provides key market data on the Canada Nephrology and Urology Devices market. The report provides value (USD million), volume (units) and average price (USD) data for each segment and sub-segment within three market categories – Incontinence Devices, Lithotripters and Renal Dialysis Equipment. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on company financials and pipeline products, wherever available.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

- Market size and company share data for Nephrology and Urology Devices market categories – Incontinence Devices, Lithotripters and Renal Dialysis Equipment.
- Annualized market revenues (USD million), volume (units) and average price (USD) data for each of the segments and sub-segments within three market categories. Data from 2004 to 2011, forecast forward for 7 years to 2018.
- 2011 company shares and distribution shares data for each of the three market categories.
- Global corporate-level profiles of key companies operating within the Canada Nephrology and Urology Devicesmarket.
- Key players covered include Fresenius Medical Care AG & Co. KGaA, Baxter International Inc., Kimberly-Clark Corporation, Svenska Cellulosa Aktiebolaget SCA, Gambro AB, B. Braun Melsungen AG and others.

Reasons to buy

- Develop business strategies by identifying the key market categories and segments poised for strong growth.
- Develop market-entry and market expansion strategies.
- Design competition strategies by identifying who-stands-where in the Canada Nephrology and Urology Devices competitive landscape.
- Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.
- What are the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize."

For further information visit http://www.reportreserve.com/report/canada-nephrology-and-urology-devices-market-outlook-to-2018-incontinence-devices-renal-dialysis-equipment-and-lithotripters-report-536892

...